163 related articles for article (PubMed ID: 20526217)
1. The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report.
Eichhoff OM; Zipser MC; Xu M; Weeraratna AT; Mihic D; Dummer R; Hoek KS
Melanoma Res; 2010 Aug; 20(4):349-55. PubMed ID: 20526217
[TBL] [Abstract][Full Text] [Related]
2. A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value.
Wouters J; Stas M; Govaere O; Barrette K; Dudek A; Vankelecom H; Haydu LE; Thompson JF; Scolyer RA; van den Oord JJ
Mod Pathol; 2014 Aug; 27(8):1088-100. PubMed ID: 24390218
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching.
Widmer DS; Hoek KS; Cheng PF; Eichhoff OM; Biedermann T; Raaijmakers MIG; Hemmi S; Dummer R; Levesque MP
J Invest Dermatol; 2013 Oct; 133(10):2436-2443. PubMed ID: 23474946
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion.
Berthier-Vergnes O; El Kharbili M; de la Fouchardière A; Pointecouteau T; Verrando P; Wierinckx A; Lachuer J; Le Naour F; Lamartine J
Br J Cancer; 2011 Jan; 104(1):155-65. PubMed ID: 21081927
[TBL] [Abstract][Full Text] [Related]
6. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
Du J; Miller AJ; Widlund HR; Horstmann MA; Ramaswamy S; Fisher DE
Am J Pathol; 2003 Jul; 163(1):333-43. PubMed ID: 12819038
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Metastatic Melanoma: Correlation of MITF With Its Transcriptional Targets MLSN1, PEDF, HMB-45, and MART-1.
Zand S; Buzney E; Duncan LM; Dadras SS
Am J Clin Pathol; 2016 Sep; 146(3):353-60. PubMed ID: 27515936
[TBL] [Abstract][Full Text] [Related]
8. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
9. In vivo switching of human melanoma cells between proliferative and invasive states.
Hoek KS; Eichhoff OM; Schlegel NC; Döbbeling U; Kobert N; Schaerer L; Hemmi S; Dummer R
Cancer Res; 2008 Feb; 68(3):650-6. PubMed ID: 18245463
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.
Cheli Y; Giuliano S; Fenouille N; Allegra M; Hofman V; Hofman P; Bahadoran P; Lacour JP; Tartare-Deckert S; Bertolotto C; Ballotti R
Oncogene; 2012 May; 31(19):2461-70. PubMed ID: 21996743
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.
Anghel SI; Correa-Rocha R; Budinska E; Boligan KF; Abraham S; Colombetti S; Fontao L; Mariotti A; Rimoldi D; Ghanem GE; Fisher DE; Lévy F; Delorenzi M; Piguet V
Pigment Cell Melanoma Res; 2012 Jul; 25(4):482-7. PubMed ID: 22594792
[TBL] [Abstract][Full Text] [Related]
12. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.
Vachtenheim J; Ondrušová L
Exp Dermatol; 2015 Jul; 24(7):481-4. PubMed ID: 25866058
[TBL] [Abstract][Full Text] [Related]
13. A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression.
Dadras SS; Lin RJ; Razavi G; Kawakami A; Du J; Feige E; Milner DA; Loda MF; Granter SR; Detmar M; Widlund HR; Horstmann MA; Fisher DE
Am J Pathol; 2015 Jan; 185(1):252-65. PubMed ID: 25447045
[TBL] [Abstract][Full Text] [Related]
14. A gene expression signature of invasive potential in metastatic melanoma cells.
Jeffs AR; Glover AC; Slobbe LJ; Wang L; He S; Hazlett JA; Awasthi A; Woolley AG; Marshall ES; Joseph WR; Print CG; Baguley BC; Eccles MR
PLoS One; 2009 Dec; 4(12):e8461. PubMed ID: 20041153
[TBL] [Abstract][Full Text] [Related]
15. ABCB5 is activated by MITF and β-catenin and is associated with melanoma differentiation.
Louphrasitthiphol P; Chauhan J; Goding CR
Pigment Cell Melanoma Res; 2020 Jan; 33(1):112-118. PubMed ID: 31595650
[TBL] [Abstract][Full Text] [Related]
16. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
17. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
18. MITF pathway mutations in melanoma.
Yokoyama S; Salma N; Fisher DE
Pigment Cell Melanoma Res; 2009 Aug; 22(4):376-7. PubMed ID: 19558635
[No Abstract] [Full Text] [Related]
19. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens.
van Dinten LC; Pul N; van Nieuwpoort AF; Out CJ; Jager MJ; van den Elsen PJ
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):24-30. PubMed ID: 15623750
[TBL] [Abstract][Full Text] [Related]
20. MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression.
Strohal R; Mosser R; Kittler H; Wolff K; Jansen B; Brna C; Stingl G; Pehamberger H
Melanoma Res; 2001 Oct; 11(5):543-8. PubMed ID: 11595894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
